Google
Trusted Resources: News & Events
Latest announcements and gatherings
Voxelotor for Sickle Cell Disease Wins FDA Nod for Patients as Young as 4
Voxelotor has a novel mechanism of action. The first-in-class therapy regulates the affinity of hemoglobin for oxygen, resulting in a decrease in the concentration of deoxygenated sickle hemoglobin (HbS), which forms polymers. It’s hypothesized that because oxygenated HbS cannot polymerize, modifying HbS to increase the proportion of oxygenated to deoxygenated HbS in red blood cells would alter disease severity.
The FDA Friday approved the wider use of voxelotor (Oxbryta) in patients with sickle cell disease (SCD) as young as 4 years of age. In 2019, the oral polymerization inhibitor was approved by the FDA for adults and pediatric patients with SCD 12 years of age and older.
+myBinderRelated Content
-
Flying doctor takes to the skies after sister’s deathOlamide Orekunrin was studying to become...
-
Disease knowledge, illness perceptions, and quality of life in adolescents with sickle cell disease: Is there a link...Disease knowledge, illness perceptions, ...
-
Restrictive cardiomyopathy is associated with nephropathy in sickle cell anemiaBackground: Cardiopulmonary and renal c...
-
Christiana Care Sickle Cell ProgramChristiana Care is one of the country’...
-
Robert I. Liem, MD, MSRobert I. Liem is Associate Professor of...
-
Spectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study FindsThe blood-separation device Spectra Opti...
-
Yutaka Niihara, MD, MPHDr. Niihara has been involved in patient...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.